Inventor
SIDDIQUI-JAIN ADAM
US32 patents
⚠️ This page may combine multiple inventors who share the name “SIDDIQUI-JAIN ADAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TOLERO PHARMACEUTICALS INC
8 patentsUS10259835B2Apr 16, 2019
Alvocidib prodrugs having increased bioavailability
TOLERO PHARMACEUTICALS INC17 citations94
US9758539B2Sep 12, 2017
Alvocidib prodrugs having increased bioavailability
TOLERO PHARMACEUTICALS INC24 citations94
US10267787B2Apr 23, 2019
Profiling peptides and methods for sensitivity profiling
TOLERO PHARMACEUTICALS INC13 citations91
US10132797B2Nov 20, 2018
Profiling peptides and methods for sensitivity profiling
TOLERO PHARMACEUTICALS INC15 citations91
US10682356B2Jun 16, 2020
Combination therapies for treatment of cancer
TOLERO PHARMACEUTICALS INC7 citations84
US10568887B2Feb 25, 2020
Combination therapies for treatment of cancer
TOLERO PHARMACEUTICALS INC10 citations84
US10562925B2Feb 18, 2020
Alvocidib prodrugs having increased bioavailability
TOLERO PHARMACEUTICALS INC10 citations84
US10422788B2Sep 24, 2019
Profiling peptides and methods for sensitivity profiling
TOLERO PHARMACEUTICALS INC11 citations82
SUMITOMO PHARMA ONCOLOGY INC
8 patentsUS11530231B2Dec 20, 2022
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
SUMITOMO PHARMA ONCOLOGY INC5 citations81
US11497756B2Nov 15, 2022
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
SUMITOMO PHARMA ONCOLOGY INC4 citations72
US12338261B2Jun 24, 2025
Alvocidib prodrugs having increased bioavailability
SUMITOMO PHARMA ONCOLOGY INC0 citations62
US11471456B2Oct 18, 2022
Formulations comprising heterocyclic protein kinase inhibitors
SUMITOMO PHARMA ONCOLOGY INC0 citations62
US12077554B2Sep 3, 2024
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
SUMITOMO PHARMA ONCOLOGY INC0 citations60
US11400091B2Aug 2, 2022
AXL kinase inhibitors and use of the same
SUMITOMO PHARMA ONCOLOGY INC0 citations54
US11529350B2Dec 20, 2022
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
SUMITOMO PHARMA ONCOLOGY INC0 citations51
US11746103B2Sep 5, 2023
ALK-5 inhibitors and uses thereof
SUMITOMO PHARMA ONCOLOGY INC0 citations46
CYLENE PHARMACEUTICALS INC
5 patentsUS7381720B2Jun 3, 2008
Substituted quinobenzoxazine analogs
CYLENE PHARMACEUTICALS INC15 citations92
US7326702B2Feb 5, 2008
Substituted quinobenzoxazine analogs
CYLENE PHARMACEUTICALS INC13 citations92
US7141565B1Nov 28, 2006
Substituted quinobenzoxazine analogs
CYLENE PHARMACEUTICALS INC34 citations92
US7612063B2Nov 3, 2009
Substituted quinobenzoxazine analogs
CYLENE PHARMACEUTICALS INC11 citations83
US7507727B2Mar 24, 2009
Substituted quinobenzoxazine analogs and methods of using thereof
CYLENE PHARMACEUTICALS INC11 citations83
SUMITOMO DAINIPPON PHARMA ONCOLOGY INC
5 patentsUS10835537B2Nov 17, 2020
Combination therapies for treatment of cancer
SUMITOMO DAINIPPON PHARMA ONCOLOGY INC7 citations83
US11034710B2Jun 15, 2021
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
SUMITOMO DAINIPPON PHARMA ONCOLOGY INC7 citations81
US11279694B2Mar 22, 2022
Alvocidib prodrugs and their use as protein kinase inhibitors
SUMITOMO DAINIPPON PHARMA ONCOLOGY INC6 citations73
US11013741B1May 25, 2021
AXL kinase inhibitors and use of the same
SUMITOMO DAINIPPON PHARMA ONCOLOGY INC1 citations66
US11040038B2Jun 22, 2021
Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
SUMITOMO DAINIPPON PHARMA ONCOLOGY INC1 citations59
FROST BIOLOGIC INC
4 patentsUS10016398B2Jul 10, 2018
Antimitotic amides for the treatment of cancer and proliferative disorders
FROST BIOLOGIC INC7 citations83
US11129813B2Sep 28, 2021
Antimitotic amides for the treatment of cancer and proliferative disorders
FROST BIOLOGIC INC1 citations72
US10772872B2Sep 15, 2020
Antimitotic amides for the treatment of cancer and proliferative disorders
FROST BIOLOGIC INC3 citations72
US12383533B2Aug 12, 2025
Antimitotic amides for the treatment of cancer and proliferative disorders
FROST BIOLOGIC INC0 citations61